Will CryoLife, Inc. (NYSE:CRY) Meet or Beat $0.1 EPS

Sell-side Wall Street brokerage firms are projecting that CryoLife, Inc. (NYSE:CRY) will post earnings of $0.05 per share when the company releases their quarterly report today. 

Most recently CryoLife, Inc. (NYSE:CRY) reported a surprise factor of 80%. The actual number was $0.04 away from the Zacks consensus just prior to the actual release. A significant surprise factor can lead to stock swings in the price in the hours and days following the earnings report.

Projected Stock Movement
Research analysts covering shares of CryoLife, Inc. (NYSE:CRY) are anticipating on a consensus basis that the stock will reach $21.75 within the next 52 weeks. Of the analysts providing short term targets, the most bullish analyst has a $23.5 target on the stock. On the other end, the most conservative has a short term target of $20. This is based on the 2 analysts taken into consideration by Zacks. The consensus price target was last revised on 2017-04-27.

Zacks also provides a simplified scale for analyst recommendations. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. CryoLife, Inc. (NYSE:CRY) currently has an ABR of 1 heading into today’s announcement. This number is also based on the 2 sell-side firms polled by Zacks.

Some stock market investors may abide to the saying, nothing ventured nothing gained. Others may operate by following the saying slow and steady wins the race. The correct move for one investor may not be the same for another. Some may choose to go all in, while others may look to reduce risk with stable long-term staple companies. Active equity investors may be forced to make hard decisions at some point, but working hard and being prepared may prove to be a portfolio booster. Dedicated investors are often willing to put in the extra hours in order to make sure no stone is left unturned.

This article is informational purposes only and should not be considered a recommendation to buy or sell CryoLife, Inc.. 

Leave a Comment